Evidence map›Paper›PMID 39955308›Full record

ArticleCell death discovery2025

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells.

Alvina I Khamidullina, Margarita A Yastrebova, Alexandra V Bruter, Julia V Nuzhina, Nadezhda E Vorobyeva, Anastasia M Khrustaleva, Ekaterina A Varlamova, Alexander V Tyakht, Iaroslav E Abramenko, Ekaterina S Ivanova and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alvina I KhamidullinaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia. 94Alvina@gmail.com.
Margarita A YastrebovaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Alexandra V BruterCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Julia V NuzhinaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Nadezhda E VorobyevaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Anastasia M KhrustalevaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Ekaterina A VarlamovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Alexander V TyakhtInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Iaroslav E AbramenkoInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Ekaterina S IvanovaBlokhin National Medical Research Center of Oncology, 24 Kashirskoye shosse, 115522, Moscow, Russia.
Maria A ZamkovaInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Jing LiDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA.
Chang-Uk LimDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA.
Mengqian ChenDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA.
Eugenia V BroudeDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA.
Igor B RoninsonDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC, 29208, USA.ORCID http://orcid.org/0000-0002-9211-1327
Alexander A ShtilInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia.
Victor V TatarskiyInstitute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov Street, 119334, Moscow, Russia. tatarskii@gmail.com.ORCID http://orcid.org/0000-0002-9080-5683

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation of circumventing signaling pathways and quiescence may limit BCR-ABLi efficacy. CDK8/19 Mediator kinases have been implicated in the emergence of non-genetic drug resistance. Dissecting the effects of pharmacological CDK8/19 inhibition on CML survival in response to BCR-ABLi, we found that a selective, non-toxic CDK8/19 inhibitor (CDK8/19i) Senexin B (SenB) and other CDK8/19i sensitized K562 cells to different BCR-ABLi via attenuation of cell cycle arrest. In particular, SenB prevented IM-induced upregulation of genes that negatively regulate cell cycle progression. SenB also antagonized IM-activated p27

Identifiers

PMID39955308
PMCPMC11830074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.